Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Antinociceptive activity of methanolic extract of Muntingia calabura leaves: further elucidation of the possible mechanisms

  • Zainul Amiruddin Zakaria1, 3Email author,
  • Mohd Hijaz Mohd Sani1,
  • Manraj Singh Cheema1,
  • Arifah Abdul Kader2,
  • Teh Lay Kek3 and
  • Mohd Zaki Salleh3
BMC Complementary and Alternative MedicineThe official journal of the International Society for Complementary Medicine Research (ISCMR)201414:63

DOI: 10.1186/1472-6882-14-63

Received: 17 October 2013

Accepted: 11 February 2014

Published: 20 February 2014

Abstract

Background

Muntingia calabura (Elaecoparceae) is a medicinal plant traditionally used, particularly, by the Peruvian people to alleviate headache and cold, pain associated with gastric ulcers or to reduce the prostate gland swelling. Following the recent establishment of antinociceptive activity of M. calabura leaf, the present study was performed to further elucidate on the possible mechanisms of antinociception involved.

Methods

The methanol extract of M. calabura (MEMC) was prepared in the doses of 100, 250 and 500 mg/kg. The role of bradykinin, protein kinase C, pottasium channels, and various opioid and non-opioid receptors in modulating the extract’s antinociceptive activity was determined using several antinociceptive assays. Results are presented as Mean ± standard error of mean (SEM). The one-way ANOVA test with Dunnett's multiple comparison was used to analyze and compare the data, with P < 0. 05 as the limit of significance.

Results

The MEMC, at all doses, demonstrated a significant (p < 0.05) dose-dependent antinociceptive activity in both the bradykinin- and phorbol 12-myristate 13-acetate (PMA)-induced nociception. Pretreatment of the 500 mg/kg MEMC with 10 mg/kg glibenclamide (an ATP-sensitive K+ channel inhibitor), the antagonist of μ-, δ- and κ-opioid receptors (namely 10 mg/kg β-funaltrexamine, 1 mg/kg naltrindole and 1 mg/kg nor-binaltorphimine), and the non-opioid receptor antagonists (namely 3 mg/kg caffeine (a non-selective adenosinergic receptor antagonist), 0.15 mg/kg yohimbine (an α2-noradrenergic antagonist), and 1 mg/kg pindolol (a β-adrenoceptor antagonist)) significantly (p < 0.05) reversed the MEMC antinociception. However, 10 mg/kg atropine (a non-selective cholinergic receptor antagonist), 0.15 mg/kg prazosin (an α1-noradrenergic antagonist) and 20 mg/kg haloperidol (a non-selective dopaminergic antagonist) did not affect the extract's antinociception. The phytochemicals screening revealed the presence of saponins, flavonoids, tannins and triterpenes while the HPLC analysis showed the presence of flavonoid-based compounds.

Conclusions

The antinociceptive activity of MEMC involved activation of the non-selective opioid (particularly the μ-, δ- and κ-opioid) and non-opioid (particularly adenosinergic, α2-noradrenergic, and β-adrenergic) receptors, modulation of the ATP-sensitive K+ channel, and inhibition of bradikinin and protein kinase C actions. The discrepancies in MEMC antinociception could be due to the presence of various phytochemicals.

Keywords

Muntingia calabura Elaecocarpaceae Methanol extract Antinociceptive activity Mechanisms of action

Background

Pain, as defined by the International Association for the Study of Pain (IASP), is “an unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” The definition empathizes pain as a complex multidimensional sensory-perceptual phenomenon that represents a unique subjective experience for each individual [1]. Pain is usually considered as a warning signal of actual or perceived tissue damage. In other word, pain which is produced by an external stimulus can therefore elicit reflex and conscious avoidance reaction to protect the body from potential harms. Nevertheless, pain can occur in the absence of tissue damage, even though the experience may be described as if the damage has occurred [2].

Receptors have their respective field or defined area from which they receive information. These nerve endings respond to noxious stimuli and transmit the information via afferent or sensory fibers to the CNS [3]. The dorsal horn is the gray matter in the posterior aspect of the spinal cord which is highly involved in pain integration, modification and relay. Pain impulses exit dorsal horn and ascend the spinal cord to the higher processing centers of the brain. The predominant pathways for pain conduction are the spinothalamic tract which synapse in the thalamus, and the spinoreticulothalamic tract which synapses in the reticular formation. The distinction in function of these two paths is not known [4]. Through pharmacological manipulation, it is possible to alter pain by decreasing transmission of pain signals to the brain or by increasing the inhibitory signal from the CNS [5].

Focusing on natural products as an alternative to many medications has been a major interest among scientists nowadays. Natural products as referred to Holt and Chandra [6] are herbs, herbal concoctions, dietary supplements, traditional Chinese medicines or alternative medicines. Natural product research is guided by ethnopharmacological knowledge and has brought substantial contributions to drug innovation by providing novel chemical structures and/or mechanism of actions [7]. Muntingia calabura, the sole species in the genus Muntingia, has been widely used as a traditional medication in the Southeast Asia and tropical America [8, 9] to treat headaches and gastric ulcer, and as an emmenogogue, antidyspeptic, antispasmodic, diaphoretic, tranquillizer and tonic [8, 10].

Scientifically, various medicinal properties have been reported, including anti-tumor [8, 11], antibacterial [12, 13], anti-inflammatory, antipyretic and antinociceptive [14, 15], antiproliferative and antioxidant [16], antihypertensive [17] and antiulcer [18] activities. With regards to the antinociceptive mechanisms, several papers have reported on the involvement of various receptor systems (e.g. opioid, atropine, phenoxybenzamine, yohimbine, pindolol, haloperidol and bicuculline), L-arginine/nitric oxide/cyclic guanosine monophosphate pathway, vanilloid receptors and glutamatergic system in the modulation of antinociceptive activity of M. calabura extracts, namely the aqueous and chloroform extracts [1922]. Moreover, it is suggested that the synergistic effect of the bioactive compounds, flavonoids, saponins, tannins and steroids, played an important role in the observed activities [16]. Recently, we have proved that the methanol extract of M. calabura (MEMC) leaves possesses good therapeutic effect in reducing nociceptive response [23] and further study by Mohd. Yusof et al. [24] leads to the isolation of 4 flavonoid-based antinociceptive-bearing bioactive compounds, of which one is a new compound called calaburone (8-hydroxy-6-methoxyflavone) and three were known compounds, namely 5-hydroxy-3,7,8-trimethoxyflavone, 3,7-dimethoxy-5-hydroflavone and 2’,4’-dihydroxy-3’-methoxychalcone. In this study, we further evaluate the possible mechanisms involved in the antinociceptive activity of the MEMC.

Methods

Plant collection

The leaves of M. calabura, collected from its natural habitat in Shah Alam, Selangor, Malaysia, were reidentified by Mr. Shamsul Khamis from the Institute of Bioscience (IBS), Universiti Putra Malaysia (UPM), Serdang, Selangor, Malaysia. A voucher specimen (SK 964/04) has been deposited in the Herbarium of the Laboratory of Natural Products, IBS, UPM, Serdang, Selangor, Malaysia.

Preparation of plant extract

This procedure was carried out as described in detail by Zakaria et al. [19]. Briefly, 500 g of matured leaves that have been air-dried for 1-2 weeks at room temperature (27 ± 2°C) and grinded into powder were soaked in methanol in the ratio of 1:20 (w/v) for 72 hours. After that, the supernatant was filtered using steel filter, cotton, and Whatman no. 1 filter paper. The residue was subjected to the same procedures for another two times. The supernatant collected from each extraction was pooled together and then subjected to evaporation process using a rotary evaporator at 40°C under reduced pressure. The crude extract obtained was used to prepare the desired dose of treatment by dissolving them into 10% DMSO.

Drugs and chemicals

The drugs apamin, charybdotoxin, tetraethylammonium chloride, atropine, haloperidol, pindolol, yohimbine, prazosin, phenylpherine, clonidine, caffeine, glibenclamide, β-funaltrexamine, naltrindole, nor-binaltorphimine, all purchased from Sigma Aldrich (U.S.A.) and bradykinin (Tocris Bioscience, U.K.), were prepared at the desired dose by dissolving them in distilled water (dH2O). Phorbol 12-myristate 13-acetate (Sigma Aldrich, USA) was dissolved in PBS solution. Acetic acid and dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific (U.K.).

Animals

Male ICR mice (25–30 g; 5–7 weeks old) and male Sprague-dawley rats (150-180 g) obtained from the Veterinary Animal Unit, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Malaysia, and kept under room temperature (27 ± 2°C; 70–80% humidity; 12 h light/darkness cycle) in the Animal Holding Unit (UPM), were supplied with food and water ad libitum up to the beginning of the experiments. The rats were, at all times, handled in accordance with current UPM guidelines for the care of laboratory animals and the ethical guidelines for investigations of experimental pain in conscious animals [25]. The study protocol of the present study was approved by the Animal House and Use Committee, Faculty of Medicine and Health Sciences, UPM (Ethical approval no.: UPM/FPSK/PADS/BR-UUH/00404). All experiments were conducted between 09.00 and 16.00 h to minimize the effects of environmental changes.

Phytochemical and HPLC analysis of MEMC

Phytochemical screening of dried leaves and MEMC

The phytochemical screening of dried leaves of M. Calabura and MEMC was performed according to the standard screening tests and conventional protocols as adopted by Zakaria et al. [16].

HPLC analysis of MEMC

The HPLC analysis of MEMC was performed according to method by Balan et al. [18] with slight modification. Briefly, 10 mg of MEMC was dissolved in 1 ml methanol and then filtered through the membrane filter (pore size 0.45 μm). A Waters Delta 600 with 600 Controller and Waters 2996 Photodiode Array (Milford, MA, USA) equipped with an autosampler, online degasser and column heater was used to analyze the filtered sample. Data was evaluated and processed using the installed Millenium 32 Software (Waters Product). The filtered samples were separated at 27°C on a minibore Phenomenex Luna 5 μm C18 column (dimensions 250 × 4.60 mm)\using a one-step linear gradient. The solvents were (A) 0.1% aqueous formic acid and (B) acetonitrile and the elution system was as follows: Initial conditions were 95% A and 5% B with a linear gradient reaching 25% B at t = 12 min. This was maintained for 8 min after which the programm decreased to 15% B at t = 22 min and was maintained for another 8 min. The programm then was returned to the initial solvent composition at t = 35 min. The flow rate used was 1.0 ml/min and the injection volume was 10 μl. The HPLC was monitored at 254 and 366 nm.

Antinociceptive assays

Involvement of protein kinase C

The experiment was conducted based on the previously described method by Savegnago et al. [26]. A volume of 50 μl of PMA (a protein kinase C activator) solution (0.05 μg/paw) was injected into the ventral surface of the right hind paw of the rat 60 min after the oral administration of vehicle, ASA (100 mg/kg) or MEMC (100, 250 and 500 mg/kg). The animals were observed individually from 15-45 min following PMA injection and the amount of time the rat spent licking the injected paw was recorded using a chronometer.

Bradykinin-induced nociception

Based on the method previously described by Ferreira et al. [27], bradykinin (10 nmol/paw in 50 μl) was injected into the plantar ventral surface of the right hind paw 60 min after the oral administration of vehicle, ASA (100 mg/kg) or MEMC (100, 250 and 500 mg/kg). The induced-rat was observed individually for 10 min, and the amount of time they spent licking the injected paw was recorded.

Involvement of potassium channels

To determine the contribution of K+ channels in MEMC-induced antinociception a method previously described by Alves and Duarte [28] was used. Mice were pre-treated with glibenclamide (an ATP sensitive K+ channel inhibitor; 10 mg/kg, i.p.), apamin (an inhibitor of small conductance Ca2+-activated K+ channels, 0.04 mg/kg, i.p.), charybdotoxin (an inhibitor of large conductance Ca2+-activated K+ channels, 0.02, i.p.) or tetraethylammonium chloride (a non-selective voltage dependant K+ channel inhibitor, 4 mg/kg, i.p.) 15 min before oral administration of either vehicle or MEMC (500 mg/kg). Sixty minutes later, pain was induced using 0.6% acetic acid. The number of writhing was recorded for 25 min, 5 min following acetic acid injection.

Effect of various receptor antagonists on MEMC-induced antinociception

The doses of drug administered to elucidate the possible involvement of the following receptor system was based on the method previously described by De Souza et al. [29], followed by pain induction using acetic acid-induced abdominal writhing test described by Mohd. Sani et al. [23]. Groups of animal were pre-treated with caffeine (3 mg/kg, i.p.), atropine (10 mg/kg, i.p.), haloperidol (20 mg/kg, i.p.), pindolol (1 mg/kg. i.p.), yohimbine (0.15 mg/kg, i.p), prazosin (0.15 mg/kg, i.p), phenylphrine (10 mg/kg, i.p.) or clonidine (0.15 mg/kg, i.p.) 15 minutes before the administration of MEMC (500 mg/kg, p.o). The pain was induced using 0.6% acetic acid 60 minutes after the administration of MEMC or vehicle. The number of writhing was counted cumulatively over the period of 25 minutes, 5 minutes following acetic acid injection.

Analysis of opioid receptor subtypes

Evaluation of opioid receptor subtype involvement was done using an abdominal constriction test which is similar to previously described methods [30, 31]. The doses of the opioid antagonists and timing of administration were based on previous studies conducted by Choi et al. [30] and Reeta et al. [31]. The μ opioid antagonist, β-funaltraxamine (β-FNA; 10 mg/kg, i.p.), δ opioid receptor antagonist, naltrindole (NALT; 1 mg/kg. i.p.) or κ opioid receptor antagonist, nor-binaltorphimine (nor-BNI; 1 mg/kg, i.p.) were administered 90 min, 15 min and 30 min respectively, before oral administration of 500 mg/kg of MEMC. The nociceptive stimuli was injected 60 minutes after MEMC administration.

Statiscal analysis

The results are presented as Mean ± standard error of mean (SEM). The one-way ANOVA test with Dunnett's multiple comparison was used to analyze and compare the data, with P < 0. 05 as the limit of significance.

Result

Phytochemical screening and HPLC analysis of MEMC

Table 1 showed the present of flavonoids, triterpenes, tannins, saponins and steroids in both the dried leaves and MEMC. There is, however, no alkaloids present based on the performed phytochemical screening. The HPLC profile of MEMC showed five major peaks at the wavelength of 254 and 366 nm (Figure 1A). The best isolation of the detected peaks (4 peaks) was observed at the wavelength of 366 nm. The four major peaks appeared in the chromatogram at the 366 nm wavelength tested at retention times of 20.436, 21.26, 22.756 and 23.52 min. Further analysis demonstrated that the five peaks showed λmax values in the region of 216.6-278, 209.6-352.9, 224.8-364.2, 221.3-347 and 229.5-350.6 nm, respectively (Figure 1B).
Table 1

Comparison on the phytochemical constituents between the leaves of M. calabura and MEMC

Phytochemical constituent

Sample

Result

Conclusion

Alkaloid

MC

-

Not detected

 

MEMC

-

Not detected

Saponin

MC

1+

Saponin was detected

 

MEMC

1+

Saponin was detected

Flavonoid

MC

1+

Flavonoid was detected

 

MEMC

1+

Flavonoid was detected

Tannins and polyphenolic compounds

MC

1+

Condensed tannins were detected

 

MEMC

1+

Condensed tannins were detected

Triterpene

MC

3+

Triterpene was detected

 

MEMC

1+

Triterpene was detected

Steroid

MC

3+

Steroid was detected

 

MEMC

2+

Steroid was detected

For saponins: + – 1-2 cm froth; ++ – 2-3 cm froth; +++ – >3 cm froth.

For flavonoids, tannins, triterpenes and steroids: + – weak colour; ++ – mild colour; +++ – strong colour.

For akalioids: + – negligible amount of precipitate; ++ – weak precipitate; +++ – strong precipitate.

https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig1_HTML.jpg
Figure 1

The HPLC profile of MEMC. (A). The HPLC chromatograms of MEMC at the wavelengths of 254 and 366 nm.; B). The UV spectra analysis of MEMC demonstrated the presence of five major peak, namely peak 1 (RT = 19.125 min), peak 2 (RT = 20.436 min), peak 3 (RT = 21.26 min), peak 4 (RT = 22.756 min) and peak 5 (RT = 23.52 min), which were observed at their respective λmax at the respective region of 216.6-278, 209.6-352.9, 224.8-364.2, 221.3-347 and 229.5-350.6 nm, suggesting, in part, the presence of flavonoid-based compounds.; and; C) Chromatogram of MEMC at 254 nm showing the presence of flavonoids type compounds, namely rutin, quercitrin, and fisetin, based on the comparison of their respective UV spectra analysis.

Evaluation of protein kinase C and bradykinin receptor in MEMC-induced antinociception

Figure 2 shows that the oral administration of 100, 250 and 500 mg/kg MEMC produced significant (p < 0.01 and p < 0.001) inhibition of PMA-induced nociception in rat. Interestingly, the 500 mg/kg MEMC exerted antinociceptive activity which was of similar intensity to that of 100 mg/kg ASA indicated by the similar percentage of analgesia recorded (58.55% and 55.36% respectively).
https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig2_HTML.jpg
Figure 2

The antinociceptive activity of MEMC against PMA-induced paw licking. Each column represents the mean ± S.E.M. of six rats. Control (C: 10% DMSO, p.o.), Phorbol-12 myristate-13 acetate (PMA; 0.05 μg/50 μL/paw), MEMC (100, 250 and 500 mg/kg, p.o.) and acetylsalicylic acid (ASA: 100 mg/kg, p.o.). **, p < 0.01 and ***, p < 0.001 when compared to control group.

As seen in Figure 3, MEMC given orally exhibits significant (p < 0.05) inhibition in a dose-dependant manner on the nociception caused by intra-plantar injection of bradykinin (10 nmol/paw) in rat. The maximal inhibition observed was 53.92% for the dose of 500 mg/kg MEMC. Similar inhibitory effect was observed for 100 mg/kg ASA.
https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig3_HTML.jpg
Figure 3

The antinociceptive effect of MEMC against bradykinin-induced paw licking. Each column represents the mean ± S.E.M. of six rats. Control (C: 10% DMSO, p.o.), bradykinin (10 nmol/paw), MEMC (100, 250 and 500 mg/kg, p.o.) and acetylsalicylic acid (ASA: 100 mg/kg, p.o.). ***, p < 0.001 when compared to control group.

Involvement of potassium channels and, non-opioid and opioid receptors on MEMC-induced antinociception

Figure 4 shows the involvement of potassium channels in the modulation of MEMC-induced antinociceptive activity. Pretreatment with glibenclamide (10 mg/kg, i.p.), apamin (0.04 mg/kg, i.p.), charybdotoxin (0.02, i.p.) and tetraethylammonium chloride (4 mg/kg, i.p.), significantly (p < 0.01) reversed the antinociceptive activity of MEMC (500 mg/kg) when assessed using acetic acid-induced abdominal writhing test.
https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig4_HTML.jpg
Figure 4

The effect of pre-treatment with glibenclamide, apamin, charybdotoxin and tetraethylammonium chloride in MEMC-induced antinociception against acetic acid-induced abdominal writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Vehicle (10% DMSO, p.o.), MEMC (500 mg/kg, p.o.), glibenclamide (GLIB: 10 mg/kg, i.p.), apamin (APA: 0.04 mg/kg, i.p.), tetraethylammonium chloride (TEA: 0.01 mg/kg, i.p.). ***, P < 0.001, **, p < 0.01 and *, p < 0.05 when compared to MEMC-treated group.

The antinociceptive activity of MEMC was also significantly (p < 0.05) reversed following intraperitoneal administration of 3 mg/kg caffeine (Figure 5), 10 mg/kg atropine (Figure 6), 0.15 mg/kg yohimbine (Figure 7), 0.2 mg/kg haloperidol (Figure 8), 0.2 mg/kg pindolol (Figure 9), or naltrindole, nor-binaltorphimine and β-funaltrexamine (Figure 10).
https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig5_HTML.jpg
Figure 5

The involvement of the adenosinergic system in MEMC-induced antinociception against acetic acid-induced abdominal writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Control (C: 10% DMSO, p.o.), Caffeine (3 mg/kg, i.p.), and MEMC (500 mg/kg, p.o.). ap < 0.001 significantly different from control group; bp < 0.001 significantly different when compared caffeine-treated group; cp < 0.001 when compared to MEMC-treated group.

https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig6_HTML.jpg
Figure 6

The involvement of the cholinergic system in MEMC-induced antinociception against acetic acid-induced abdominal writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Control (C: 10% DMSO, p.o.), atropine (10 mg/kg, i.p.), and MEMC (500 mg/kg, p.o.). ap < 0.001 significantly different from control group; bp < 0.001 significantly different when compared atropine-treated group.

https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig7_HTML.jpg
Figure 7

The involvement of the adrenergic system in MEMC-induced antinociception against acetic acid-induced abdominal writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Control (C: 10% DMSO, p.o.), prazosin (PRA: 0.15 mg/kg, i.p.), Phenylphrine (PHE: 10 mg/kg, i.p.), Yohimbine (YOH: 0.15 mg/kg, i.p.), Clonidine (CLO: 0.15 mg/kg, i.p.) and MEMC (500 mg/kg, p.o.). ap < 0.05 significantly different from control group; #p < 0.05 significantly different when compared between respected treatment groups.

https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig8_HTML.jpg
Figure 8

The involvement of the dopaminergic system in MEMC-induced antinociception against acetic acid-induced abdominal writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Control (C: 10% DMSO, p.o.), Haloperidol (20 mg/kg, i.p.), and MEMC (500 mg/kg, p.o.). ap < 0.001 significantly different from control group; bp < 0.001 significantly different when compared haloperidol-treated group.

https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig9_HTML.jpg
Figure 9

The involvement of the serotonergic system in MEMC-induced antinociception against acetic acid-induced abdominal writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Control (C: 10% DMSO, p.o.), Pindolol (1 mg/kg, i.p.), and MEMC (500 mg/kg, p.o.). ap < 0.001 significantly different from control group; bp < 0.001 significantly different when compared pindolol-treated group; cp < 0.01 when compared to MEMC-treated group.

https://static-content.springer.com/image/art%3A10.1186%2F1472-6882-14-63/MediaObjects/12906_2013_Article_1674_Fig10_HTML.jpg
Figure 10

Analysis of opioid receptor subtypes involvement in MEMC-induced antinociception against acetic acid-induced writhing test inn mice. Control (C: 10% DMSO, p.o.), MEMC (500 mg/kg, p.o.), naloxone (NLX: 5 mg/kg, i.p.), naltrindole (NALT: 1 mg/kg, i.p.), β-funaltrexamine (β-FNA: 10 mg/kg, i.p.), nor-binaltorphimine (nor-BNI: 1 mg/kg, i.p.) and acetylsalicylic acid (ASA: 100 mg/kg, p.o.). ***P < 0.001 when compared to the group treated only with MEMC; **p < 0.01 when compared to the group treated only with MEMC.

Discussion

Previous studies conducted in our laboratory demonstrates the ability of the MEMC to produce significant antinociceptive activity in both chemicals- and thermal-induced nociception test model indicating possible participation of central and peripheral antinociceptive mechanisms. The present study focuses further on the mechanisms of action involved in antinociception induced by crude methanol extract from the leaves of M. calabura. The results obtained revealed that the oral administration of MEMC produced significant dose-dependant inhibition of intraplantar (i.pl.) injection of bradykinin- and PMA-induced nociception.

Protein kinase C (PKC) has been reported to indirectly involved in the central sensitization of normally silent N-methyl D-aspartate (NMDA) glutamate receptors located in the postsynaptic neuron [32, 33], suggesting that the activation of PKC also play important role in the nociceptive transmission through a glutamatergic system. The i.pl. administration of PMA causes nociception, thermal hyperalgesia as well as mechanical allodynia in experimental animal model [34]. Based on the above statements, our data further strengthen the involvement of MEMC in central mechanism of antinociception as reported previously [23]. The activation of PKC occurs through interaction with intracellular lipid second messenger phosphatidylserine and diacylglycerol (DAG), and high level of calcium ions [35], which leads to the phosphorylation of many cellular components including the modulation of TRPV1 receptor [3638]. Based on our findings, MEMC caused significant reduction in the nociceptive response induced by PMA in a dose-dependent manner, which in turn prevents the phosphorylation of TRPV1. This correlates well with our previous finding [23] where we demonstrated the possible involvement of TRPV1 in MEMC-induced antinociception through capsaicin-induced paw licking test. We, therefore, suggest that the MEMC antinociceptive activity involved partly the inhibition of TRPV1 receptor phosphorylation via attenuation of the PKC activation.

It is reported that PKC can also be directly activated by binding of bradykinin to its receptor [27]. This view was supported by our results demonstrating the MEMC's ability to suppress the nociception caused by bradykinin. Bradykinin is a potent inflammatory peptide messenger which is generated from a protein precursor, kallidin, through the action of specific enzyme kallikrein. During injury or inflammation, bradykinin will be released from the damaged tissues, from mast cells, as well as produced in the blood where it serves as vasodilators and increases vessel permeability [35]. This peptide is considered as one of the most potent pain-producing substance as it not only excites plenty of nociceptors, but also sensitizes them to other noxious stimuli through activation of B1 and B2 receptors [35, 39].

Bradykinin acted through G-coupled protein receptor, on dorsal root ganglion (DRG) sensory neurons, elicits marked increase in Ca2+, through activation of DAG and PKC pathway [40, 41]. Peripheral sensitization by bradykinin, which acted on the Aδ and C-fibers, evoke the release and synthesis of other second messengers, including prostaglandins, nitric oxide and neurokinins [40, 42, 43]. Pain induced through the introduction of bradykinin into the right hind paw of the experimental rat is significantly inhibited by oral administration of 250 and 500 mg/kg MEMC. It has been reported that the pain induced by bradykinin can be inhibited by cyclooxygenase (COX) inhibitor indomethacin [44], and therefore this type of pain is mediated by prostaglandins (probably PGE2). The ability of MEMC to inhibit bradykinin hyperalgesia correlates well with previous report [23], which proposed that MEMC antinociceptive activity seen in acetic acid-induced nociception may occurs through the inhibition of COX, as well as other mediators mentioned above or possibly by directly blocking the B2 receptors.

The noradrenergic receptor system involved greatly in descending modulation of pain pathways. Clonidine, a α2-adrenergic agonist, acting on the nerve endings of primary afferent fibers will inhibit the release of norepinephrine, glutamate and substance P, as well as pro-inflammatory cytokines resulting in sedative and analgesic actions [45, 46]. Our findings suggested the involvement of α2-adrenergic, but excluded the α1-adrenergic receptors since MEMC activity was significantly reversed, when challenged with yohimbine (α2-adrenergic antagonist). In addition, serotonergic receptor pathway correlates with that of noradrenergic system. Activation of serotonergic receptor will cause the release of noradrenaline which activate postsynaptic α2-adrenergic in the spinal cord leading to antinociception [47, 48], and pretreatment with pindolol (5-HT1A/1B receptor/β-adrenoceptor inhibitor) significantly reversed MEMC antinociceptive activity indicating its role in serotonergic system.

We also demonstrated the involvement of adenosinergic receptor system in MEMC-induced antinociception. Caffeine, a non-selective adenosinergic receptor antagonist significantly reduced the action of MEMC. Pharmacologically, caffeine blocked adenosine A1, A2A, A2B, and A3 receptor but with lower affinity [49, 50]. Adenosine receptor activation particularly A1 produces antinociception, by reducing PGE2[51, 52] and triggers NO/cGMP/PKG/KATP pathway [53] in acute pain, and increases pain threshold [54] as well as inhibit glutamate release [55] in chronic pain. Adenosinergic and serotonergic systems are closely involved as A1 receptor antagonist can block serotonin analgesic action [56]. On the other hand, atropine (a cholinergic receptor antagonist) and haloperidol (a dopaminergic receptor antagonist) did not cause any significant changes in the number of abdominal constrictions, indicating lack of involvement of those receptor systems in MEMC antinociception.

The activation of 5-HT1A has been shown to promote the opening of K+ channels and closing of Ca+ channels through coupling negatively to adenylyl cyclase which lead to sensory transmission inhibition [57]. Corroborating to the finding, we demonstrated that pre-treatment with glibenclamide (a specific ATP-sensitive K+ channel blocker), apamin (small conductance Ca2+-activated K+ channels), charybdotoxin (an inhibitor of large conductance Ca2+-activated K+ channels) and tetraethylammonium chloride (a non-selective voltage dependant K+ channel inhibitor) significantly reversed the antinociceptive effect of MEMC. The opening of ATP-sensitive K+ channel has been reported to participate in opioid-mediated antinociception, at the level of K+ and not opioid receptor [58], since specific ATP-sensitive K+ channel blockers (glibenclamide and gliquidone) shown to dose-dependently reduce the antinociceptive of morphine [59, 60]. This correlates well with previous study demonstrating the involvement of MEMC in opioid receptor system [23].

Previously, we have demonstrated the involvement of opioid receptor in MEMC antinociception using non-selective opioid antagonist, naloxone [23]. In the present study, we elucidated the possible role of opioid receptor subtype in the modulation of MEMC antinociception using μ, δ, and κ opioid antagonists. Our findings demonstrated MEMC activity was significantly attenuated by all of the opioid subtypes' antagonists, suggesting the role of those receptors in the analgesic activity of MEMC. These receptors, found throughout the nervous system, spinal cord, midbrain and cortex, can mediate pain inhibition [61], and the report showed increased expression of δ opioid receptor when μ receptors were repeatedly activated [62], which accounted for the synergistic action seen in other studies [63, 64].

The phytochemical screening shows the presence of flavonoids, triterpenes, saponins steroids and tannins which is in line with previous report [15], and interestingly all of these bioactive constituents has been reported to be involved in antinociceptive activity [6568]. Our HPLC analysis revealed the possible presence of flavonols, namely rutin, quercitrin and fisetin. The ability of quercitrin to inhibit the pro-inflammatory mediators involved in pain modulation, especially cytokines, has been reported [69]. Rutin has been reported to produced antinociceptive activity by inhibiting both COX and lipooxygenase (LOX) pathways at high concentration [70]. Various reports have demonstrated that these types of flavonoids possess significant antinociceptive and/or anti-inflammatory activities [7173].

Conclusions

We conclude that the antinociceptive activity of MEMC may also be mediated through inhibition of PKC pathway and bradykinin receptor as well as through the activation of K+ channels, adrenergic, serotonergic and adenosinergic receptor systems. Our findings also revealed the possible interaction of MEMC with the three opioid receptor subtypes. The activity seen could be due to the synergistic effect of flavonoids, saponins, tannins and steroids.

Declarations

Acknowledgements

This study was supported by the Science Fund Research Grant (Reference no. 06-01-04-SF1127) awarded by the Ministry of Science Technology and Innovation (MOSTI), Malaysia and the Research University Grant Scheme (Reference no. 04-02-12-2019RU) from the Universiti Putra Malaysia, Malaysia. The authors thanked the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia for providing the facilities to carry out this study.

Authors’ Affiliations

(1)
Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia
(2)
Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia
(3)
Integrative Pharmacogenomics Institute (iPROMISE)

References

  1. Raj PP: Pain Medicine: A Comprehensive Review. 2003, Texas: Mosby Inc, 2Google Scholar
  2. Strong J, Unruh AM, Wright A, Baxter GD, Wall PD: Pain: a textbook for therapists. 2002, London: Churchill LivingstoneGoogle Scholar
  3. Hawthorn J, Redmond K: Pain: causes and management. 1998, Oxford: Blackwell Science LtdGoogle Scholar
  4. Paris PM, Stewart RD: Pain management in emergency medicine. 1988, Connecticut: Appleton and LangeGoogle Scholar
  5. Katzung BG: Basic and Clinical Pharmacology. 2004, International Edition, 9Google Scholar
  6. Holt GA, Chandra A: Herbs in the modern healthcare environment-an overview of uses, legalities and the role of the healthcare professional. Clin Res Regul Aff (USA). 2002, 19: 83-107. 10.1081/CRP-120004219.View ArticleGoogle Scholar
  7. Rates SMK: Plants as source of drugs. Toxicon. 2001, 29: 603-View ArticleGoogle Scholar
  8. Kaneda N, Pezzuto JM, Soejarto DD, Kinghorn AD, Farnsworth NR, Santisuk T, Tuchinda P, Udchachon J, Reutrakul V: Plant anticancer agents, XLVIII. New cytotoxic flavonoids from Muntingia calabura roots. J Nat Prod. 1991, 54: 196-206. 10.1021/np50073a019.View ArticlePubMedGoogle Scholar
  9. Nshimo CM, Pezzuto JM, Kinghorn AD, Farnsworth NR: Cytotoxic constituents of Muntingia calabura leaves and stems collected in Thailand. Int J Pharmacogn. 1993, 31: 77-81. 10.3109/13880209309082922.View ArticleGoogle Scholar
  10. Perez-Arbelaez E: Plantas Medicinales y Venenosas de Colombia. Edited by: Salazar H. 1975, Colombia: Medellin, 192-Google Scholar
  11. Su BN, Jung Park E, Vigo JS, Graham JG, Cabieses F, Fong HH, Pezzuto JM, Kinghorn AD: Activity-guided isolation of the chemical constituents of Muntingia calabura using a quinone reductase induction assay. Phytochemistry. 2003, 63: 335-341. 10.1016/S0031-9422(03)00112-2.View ArticlePubMedGoogle Scholar
  12. Zakaria ZA, Fatimah CA, Mat Jais AM, Zaiton H, Henie EFP, Sulaiman MR, Somchit MN, Thenamuha M, Kasthuri D: The in vitro antibacterial activity of Muntingia calabura extracts. Int J Pharmacol. 2006, 2: 439-442.View ArticleGoogle Scholar
  13. Zakaria ZA, Sufian AS, Ramasamy K, Ahmat N, Sulaiman MR, Arifah AK, Zuraini A, Somchit MN: In vitro antimicrobial activity of Muntigia calabura extracts and fractions. Afr J Microbiol Res. 2010, 4: 304-308.Google Scholar
  14. Zakaria ZA, Mohd Nor Hazalin NA, Mohd Zaid SNH, Abdul Ghani M, Hassan MH, Gopalan HK, Sulaiman MR: Antinociceptive, anti-inflammatory and antipyretic effects of Muntingia calabura aqueous extract in animal models. J Nat Med. 2007, 61: 443-448. 10.1007/s11418-007-0167-2.View ArticleGoogle Scholar
  15. Zakaria ZA, Kumar GH, Mohd Zaid SNH, Abdul Ghani M, Hassan MH, Mohd Nor Hazalin NA, Khamis MM, Devi RG: Analgesic and antipyretic actions of Muntingia calabura leaves chloroform extract in animal models. Orient Pharm Exp Med. 2007, 7: 34-40. 10.3742/OPEM.2007.7.1.034.View ArticleGoogle Scholar
  16. Zakaria ZA, Mohammad AM, Mohd Jamil NS, Rofiee MS, Hussain MK, Sulaiman MR, Teh LK, Salleh MZ: In vitro antiproliferative and antioxidant activities of the extracts of Muntingia calabura leaves. Am J Chin Med. 2011, 39: 183-200. 10.1142/S0192415X11008749.View ArticlePubMedGoogle Scholar
  17. Shih CD, Chen JJ, Lee HH: Activation of nitric oxide signaling pathway mediates hypotensive effect of Muntingia calabura L. (Tiliaceae) leaf extract. Am J Chin Med. 2006, 34: 857-872. 10.1142/S0192415X0600434X.View ArticlePubMedGoogle Scholar
  18. Balan T, Mohd Sani MH, Suppaiah V, Mohtarrudin N, Suhaili Z, Ahmad Z, Zakaria ZA: Antiulcer activity of Muntingia calabura leaves involves the modulation of endogenous nitric oxide and nonprotein sulfhydryl compounds. Pharm Biol. 2013, doi:10.3109/13880209.2013.839713Google Scholar
  19. Zakaria ZA, Sulaiman MR, Jais AM, Somchit MN, Jayaraman KV, Balakhrisnan G, Abdullah FC: The antinociceptive activity of Muntingia calabura aqueous extract and the involvement of L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in its observed activity in mice. Fundam Clin Pharmacol. 2006, 20: 365-372. 10.1111/j.1472-8206.2006.00412.x.View ArticlePubMedGoogle Scholar
  20. Zakaria ZA, Mustapha S, Sulaiman MR, Mat Jais AM, Somchit MN, Abdullah FC: The antinociceptive action of aqueous extract from Muntingia calabura leaves: The role of opioid receptors. Med Prin Pract. 2007c, 16: 130-136. 10.1159/000098366.View ArticleGoogle Scholar
  21. Zakaria ZA, Hassan MH, Nurul Aqmar MN, Abd Ghani M, Mohd Zaid SN, Sulaiman MR, Hanan Kumar G, Fatimah CA: Effects of various nonopioid receptor antagonist on the antinociceptive activity of Muntingia calabura extracts in mice. Methods Find Exp Clin Pharmacol. 2007, 29: 515-520. 10.1358/mf.2007.29.8.1119164.View ArticlePubMedGoogle Scholar
  22. Zakaria ZA, Somchit MN, Sulaiman MR, Mat Jais AM, Fatimah CA: Effects of various receptor antagonists, pH and enzymes on Muntingia calabura antinociception in mice. Res J Pharmacol. 2008, 2: 31-37.Google Scholar
  23. Mohd Sani MH, Zakaria ZA, Balan T, Teh LK, Salleh MZ: Antinociceptive Activity of Methanol Extract of Muntingia calabura Leaves and the Mechanisms of Action Involved. Evid Based Compl Alt. 2012, doi:10.1155/2012/890361Google Scholar
  24. Mohamad Yusof MI, Salleh MZ, Lay Kek T, Ahmat N, Nik Azmin NF, Zakaria ZA: Activity-Guided Isolation of Bioactive Constituents with Antinociceptive Activity from Muntingia calabura L. Leaves Using the Formalin Test. Evid Based Compl Alt. 2013, doi:10.1155/2013/715074Google Scholar
  25. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983, 16: 109-110. 10.1016/0304-3959(83)90201-4.View ArticlePubMedGoogle Scholar
  26. Savegnago L, Pinto LG, Jesse CR, Alves D, Rocha JB, Nogueira CW, Zeni G: Antinociceptive properties of diphenyl diselenide: evidences for the mechanism of action. Eur J Pharmacol. 2007, 555: 129-138. 10.1016/j.ejphar.2006.10.003.View ArticlePubMedGoogle Scholar
  27. Ferreira J, da Silva GL, Calixto JB: Contribution of vanilloid receptors to the overt nociception induced by B2 kinin receptor activation in mice. Brit J Pharmacol. 2004, 141: 787-794. 10.1038/sj.bjp.0705546.View ArticleGoogle Scholar
  28. Alves D, Duarte I: Involvement of ATP-sensitive K(+) channels in the peripheral antinociceptive effect induced by dipyrone. Eur J Pharmacol. 2002, 444: 47-52. 10.1016/S0014-2999(02)01412-7.View ArticlePubMedGoogle Scholar
  29. De Souza MM, Pereira MA, Ardenghi JV, Mora TC, Bresciani LF, Yunes RA, Delle Monache F, Cechinel-Filho V: Filicene obtained from Adiantum cuneatum interacts with the cholinergic, dopaminergic, glutamatergic, GABAergic and tachykinergic systems to exert antinociceptive effect in mice. Pharmacol Biochem Behav. 2009, 93: 40-46. 10.1016/j.pbb.2009.04.004.View ArticlePubMedGoogle Scholar
  30. Choi SS, Han KJ, Lee HK, Han EJ, Suh HW: Possible antinociceptive mechanisms of opioid receptor antagonists in the mouse formalin test. Pharmacol Biochem Behav. 2003, 75: 121-124.View ArticleGoogle Scholar
  31. Reeta K, Mediratta PK, Rathi N, Jain H, Chugh C, Sharma KK: Role of kappa and delta opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice. Regul Pept. 2006, 135: 85-90. 10.1016/j.regpep.2006.04.004.View ArticlePubMedGoogle Scholar
  32. Basbaum AI, Bushnell MC: Science of Pain. 2009, San Diego: Elsevier Inc.Google Scholar
  33. Ji RR, Woolf CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis. 2001, 8: 1-10. 10.1006/nbdi.2000.0360.View ArticlePubMedGoogle Scholar
  34. Khalid MH, Akhtar MN, Mohamad AS, Perimal EK, Akira A, Israf DA, Lajis N, Sulaiman MR: Antinociceptive effect of the essential oil of Zingiber zerumbet in mice: possible mechanisms. J Ethnopharmacol. 2011, 137: 345-351. 10.1016/j.jep.2011.05.043.View ArticlePubMedGoogle Scholar
  35. Schmidt RF, Willis WD: Encyclopedia of pain. 2007, New York: Springer-verlag Berlin Heilberg, 1:View ArticleGoogle Scholar
  36. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D: Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature. 2001, 411: 957-962. 10.1038/35082088.View ArticlePubMedGoogle Scholar
  37. Ferreira J, Triches KM, Medeiros R, Calixto JB: Mechanisms involved in the nociception produced by peripheral protein kinase C activation in mice. Pain. 2005, 117: 171-181. 10.1016/j.pain.2005.06.001.View ArticlePubMedGoogle Scholar
  38. Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA: Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol Lond. 2001, 543: 813-825.View ArticleGoogle Scholar
  39. Riley J, Boulis NM: Molecular mechanisms of pain: a basis for chronic pain and therapeutic approaches based on the cell and the gene. Clin Neurosci. 2006, 53: 77-97.Google Scholar
  40. Mayer S, Izydorczyk I, Reeh PW, Grubb BD: Bradykinin-induced nociceptor sensitisation to heat depends on cox-1 and cox-2 in isolated rat skin. Pain. 2007, 130: 14-24. 10.1016/j.pain.2006.10.027.View ArticlePubMedGoogle Scholar
  41. Smith JA, Davis CL, Burgess GM: Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. Eur J Neurosci. 2000, 12: 3250-3258. 10.1046/j.1460-9568.2000.00218.x.View ArticlePubMedGoogle Scholar
  42. Calixto JB, Cabrini DA, Ferreira J, Campos MM: Kinins in pain and inflammation. Pain. 2000, 87: 1-5. 10.1016/S0304-3959(00)00335-3.View ArticlePubMedGoogle Scholar
  43. Sauer SK, Schafer D, Kress M, Reeh PW: Stimulated prostaglandin E2 release from rat skin, in vitro. Life Sci. 1998, 62: 2045-2055. 10.1016/S0024-3205(98)00176-3.View ArticlePubMedGoogle Scholar
  44. Janig W: Autonomic nervous system and pain. Science of Pain. Edited by: Basbaum AI, Bushnell MC. 2009, San Diego: Elsevier Inc, Volume 1:Google Scholar
  45. Bantel C, Maze M, Stone L, Wilcox G: Alpha 2-adrenergic agonists in pain treatment. Encyclopedia of pain. Edited by: Schmidt RF, Willis WD. 2007, New York: Springer-verlag Berlin Heilberg, 1Google Scholar
  46. Lavand’homme PM, Eisenach JC: Perioperative administration of the alpha2-adrenoceptor agonist clonidine at the site of nerve injury reduces the development of mechanical hypersensitivity and modulates local cytokine expression. Pain. 2003, 105: 247-254. 10.1016/S0304-3959(03)00221-5.View ArticlePubMedGoogle Scholar
  47. Carrol I, Mackey S, Gaeta R: The role of adrenergic receptors and pain: the good, the bad, and the unknown. Semin Anesth Perio M. 2007, 26: 17-21. 10.1053/j.sane.2006.11.005.View ArticleGoogle Scholar
  48. Sawynok J, Reid A: Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. Behav Brain Res. 1996, 73: 63-68.View ArticlePubMedGoogle Scholar
  49. Fredholm BB, Battig K, Holmen J, Nehlig A, Avartau EE: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999, 51: 83-133.PubMedGoogle Scholar
  50. Sawynok J: Caffeine and pain. Pain. 2011, 152: 726-729. 10.1016/j.pain.2010.10.011.View ArticlePubMedGoogle Scholar
  51. Karlsten R, Gordh T, Post C: Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice. Pharmacol Toxicol. 1992, 70: 434-438. 10.1111/j.1600-0773.1992.tb00503.x.View ArticlePubMedGoogle Scholar
  52. Taiwo YO, Levine JD: Direct cutaneous hyperalgesia induced by adenosine. Neurosci. 1990, 38: 757-762. 10.1016/0306-4522(90)90068-F.View ArticleGoogle Scholar
  53. Lima FO, Souza GR, Verri WA, Parada CA, Ferreira SH, Cunha FQ, Cunha TM: Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain. 2010, 151: 506-515. 10.1016/j.pain.2010.08.014.View ArticlePubMedGoogle Scholar
  54. Wu WP, Hao JX, Halldner L, Lövdahl C, DeLander GE, Wiesenfeld-Hallin Z, Fredholm BB, Xu XJ: Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain. 2005, 113: 395-404. 10.1016/j.pain.2004.11.020.View ArticlePubMedGoogle Scholar
  55. Nascimento FP, Macedo SJ, Santos ARS: The involvement of purinergic system in pain: adenosine receptors and inosine as pharmacological tools in future treatments. Pharmacology. Edited by: Luca G. 2012, InTech, doi:10.5772/33754Google Scholar
  56. Sawynok J: Adenosine receptor activation and nociception. Eur J Pharmacol. 1998, 347: 1-11. 10.1016/S0014-2999(97)01605-1.View ArticlePubMedGoogle Scholar
  57. Ito A, Kumamoto E, Takeda M, Shibata K, Sagai H, Yoshimura M: Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5–HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci. 2000, 20: 6302-6308.PubMedGoogle Scholar
  58. Raffa RB, Codd EE: Lack of glibenclamide or TEA affinity for opioid receptors: further evidence for in vivo modulation of antinociception at K + channels. Brain Res. 1994, 650: 146-148. 10.1016/0006-8993(94)90217-8.View ArticlePubMedGoogle Scholar
  59. Ocana M, Del Pozo E, Barrios M, Robles LI, Baeyens JM: An ATP-dependent potassium channel blocker antagonizes morphine analgesia. Eur J Pharmacol. 1990, 186: 377-378. 10.1016/0014-2999(90)90466-J.View ArticlePubMedGoogle Scholar
  60. Rodrigues AR, Duarte ID: The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K + channels. Brit J Pharmacol. 2000, 129: 110-114. 10.1038/sj.bjp.0703038.View ArticleGoogle Scholar
  61. Rittner HL, Machelska H, Stein C: Immune System, Pain and Analgesia. Science of Pain. Edited by: Basbaum AI, Bushnell MC. 2009, San Diego: Elsevier Inc, 1: 1Google Scholar
  62. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A: Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances {delta}-mediated antinociception. J Neurosci. 2001, 21: 7598-PubMedGoogle Scholar
  63. Hurley RW, Hammond DL: Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal micro opioid receptor agonists after inflammatory injury. J Neurosci. 2001, 21: 2536-PubMedGoogle Scholar
  64. Schidmt BL, Tambeli CH, Levine JD, Gear RW: mu/cooperativity and opposing opioid effects in nucleus accumbens mediated antinociception in the rat. Eur J Neurosci. 2002, 15: 861-868. 10.1046/j.1460-9568.2002.01915.x.View ArticleGoogle Scholar
  65. Beirith A, Santos ARS, Calixto JB, Hess SC, Messana I, Ferrari F, Yunes RA: Study of the antinociceptive action of the ethanolic extract and the triterpene 24-hydroxytormentic acid isolated from the stem bark of Ocotea suaveolens. Planta Med. 1999, 65: 50-55. 10.1055/s-1999-13962.View ArticlePubMedGoogle Scholar
  66. Karumi Y, Onyeyili P, Ogugbuaja VO: Anti-inflammatory and antinociceptive (analgesic) properties of Momordical balsamina Linn. (Balsam apple) leaves in rats. Pak J Biol Sci. 2003, 6: 1515-1518.View ArticleGoogle Scholar
  67. Musa AM, Aliyu AB, Yaro AH, Magaji MG, Hassan HS, Abdullahi MI: Preliminary phytochemical, analgesic and anti-inflammatory studies of the methanol extract of Anisopus mannii in rodents. Afr J Pharm Pharmacol. 2009, 3: 374-378.Google Scholar
  68. Starec M, Waitzov’a D, Elis J: Evaluation of the analgesic effect of RG-tannin using the “hot plate” and “tail flick” method in mice (in Czech). Cesk Farm. 1988, 37: 319-321.PubMedGoogle Scholar
  69. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Gálvez J, Zarzuelo A: In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 2005, 35: 584-592. 10.1002/eji.200425778.View ArticlePubMedGoogle Scholar
  70. Chua LS: A review on plant-based rutin extraction methods and its pharmacological activities. J Ethnopharmacol. 2013, 150: 805-817. 10.1016/j.jep.2013.10.036.View ArticlePubMedGoogle Scholar
  71. Calixto JB, Beirith A, Ferreira J, Santos AR, Cechinel Filho V, Yunes RA: Naturally occurring antinociceptive substances from plants. Phytother Res. 2000, 14: 401-418. 10.1002/1099-1573(200009)14:6<401::AID-PTR762>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
  72. Bittar M, de Souza MM, Yunes RA, Lento R, Delle Monache F, Cechinel Filho V: Antinociceptive activity of I3,II8-binaringenin, a biflavonoid present in plants of the guttiferae. Planta Med. 2000, 66: 84-86.View ArticlePubMedGoogle Scholar
  73. Gadotti VM, Santos ARS, Meyre-Silva C, Schmeling LO, Machado C, Liz FH, Filho VC: Antinociceptive action of the extract and the flavonoid quercitrin isolated from Bauhinia microstachya leaves. J Pharm Pharmacol. 2005, 57: 1345-1351. 10.1211/jpp.57.10.0014.View ArticlePubMedGoogle Scholar
  74. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/63/prepub

Copyright

© Zakaria et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement